alefacept + etanercept

Alefacept + etanercept is a combination of two biologic immunomodulatory drugs, both protein-based therapies, used off-label in the management of moderate to severe plaque psoriasis that is refractory to monotherapy. Alefacept is a recombinant fusion protein consisting of the extracellular CD2-binding portion of human leukocyte function antigen-3 (LFA-3) linked to the Fc portion of human IgG1. It acts by inhibiting T-cell activation through interference with CD2 on T cells and induces apoptosis in memory-effector T lymphocytes, leading to reduced psoriatic inflammation. Etanercept is a dimeric fusion protein composed of the extracellular ligand-binding domain of the human p75 tumor necrosis factor receptor (TNFR) fused to the Fc portion of IgG1. It functions as a TNF inhibitor by binding and neutralizing tumor necrosis factor alpha (TNF-α), thereby reducing inflammatory processes involved in autoimmune diseases such as psoriasis and rheumatoid arthritis. The combination has been reported in case studies for patients whose psoriasis did not respond adequately to etanercept alone; it showed clinical improvement without significant adverse events over short-term observation[2][4][6].